Management of infantile hemangiomas during the COVID pandemic.

The COVID-19 pandemic has caused significant shifts in patient care including a steep decline in ambulatory visits and a marked increase in the use of telemedicine. Infantile hemangiomas (IH) can require urgent evaluation and risk stratification to determine which infants need treatment and which can be managed with continued observation. For those requiring treatment, prompt initiation decreases morbidity and improves long-term outcomes. The Hemangioma Investigator Group has created consensus recommendations for management of IH via telemedicine. FDA/EMA-approved monitoring guidelines, clinical practice guidelines, and relevant, up-to-date publications regarding initiation and monitoring of beta-blocker therapy were used to inform the recommendations. Clinical decision-making guidelines about when telehealth is an appropriate alternative to in-office visits, including medication initiation, dosage changes, and ongoing evaluation, are included. The importance of communication with caregivers in the context of telemedicine is discussed, and online resources for both hemangioma education and propranolol therapy are provided. © 2020 Wiley Periodicals LLC.

Citation

Ilona J Frieden, Katherine B Püttgen, Beth A Drolet, Maria C Garzon, Sarah L Chamlin, Elena Pope, Anthony J Mancini, Christine T Lauren, Erin F Mathes, Dawn H Siegel, Deepti Gupta, Anita N Haggstrom, Megha M Tollefson, Eulalia Baselga, Kimberly D Morel, Sonal D Shah, Kristen E Holland, Denise M Adams, Kimberly A Horii, Brandon D Newell, Julie Powell, Catherine C McCuaig, Amy J Nopper, Denise W Metry, Sheilagh Maguiness, Hemangioma Investigator Group. Management of infantile hemangiomas during the COVID pandemic. Pediatric dermatology. 2020 May 16;37(3):412-418

Mesh Tags

Substances

PMID: 32298480

search → result